Ivabradine Pharmathen

Active Ingredient:: Ivabradine
Origin:: EU

Ivabradine Pharmathen (Ivabradine)

Q: What conditions is Ivabradine Pharmathen used to treat?

Ivabradine Pharmathen is indicated for chronic stable angina and for heart failure with reduced ejection fraction in patients who need additional heart‑rate reduction despite optimal standard therapy. It helps relieve angina symptoms and can improve functional status in heart‑failure patients.

Q: How does ivabradine work to lower heart rate?

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, which is responsible for spontaneous pacemaker activity. By inhibiting this inward Na⁺/K⁺ current, the drug slows the rate of depolarisation, resulting in a controlled reduction of heart rate without affecting contractility or blood pressure.

Q: What is the usual dose of Ivabradine Pharmathen?

The dose of Ivabradine Pharmathen is determined by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and concomitant therapies. The prescriber will select the appropriate strength and dosing schedule according to approved labeling and individual patient needs.

Q: Is Ivabradine safe to use during pregnancy or breastfeeding?

The safety of Ivabradine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

Q: How do I order Ivabradine Pharmathen from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does ivabradine compare with beta‑blockers for heart‑rate control?

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and can influence contractility and bronchial tone, making ivabradine a useful alternative when beta‑blockers are contraindicated or not tolerated.

Q: What are the recommended storage conditions for Ivabradine Pharmathen?

Ivabradine Pharmathen tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Q: How is Ivabradine Pharmathen administered?

Ivabradine Pharmathen is taken orally, usually with or without food, as directed by the prescribing physician. The tablets are swallowed whole with a glass of water and should be taken at the same times each day to maintain consistent blood levels.

Q: What are the most serious risks associated with ivabradine therapy?

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and persistent visual disturbances. Patients should be monitored for these events, especially during dose initiation and when combined with other heart‑rate‑lowering agents.

Q: Who should not take Ivabradine Pharmathen?

Ivabradine Pharmathen is contraindicated in patients with severe hypotension, sick‑sinus syndrome, acute myocardial infarction, unstable angina, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of its excipients.

Ivabradine, the active ingredient in Ivabradine Pharmathen, is a If channel inhibitor presented as an oral tablet for oral use. It is used to lower heart rate in patients with chronic stable angina and heart failure with reduced ejection fraction.
GNH India supplies Ivabradine Pharmathen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pharmathen S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine acts on the cardiac If current, providing heart‑rate reduction for specific cardiovascular conditions.
Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance.
Heart failure with reduced ejection fraction: lowers resting heart rate, improving symptoms and decreasing hospitalisations.
Patients with a resting heart rate ≥70 bpm despite optimal therapy: helps achieve target heart‑rate control when added to standard treatment.

How It Works

Ivabradine selectively binds to the funny (If) channels in the sinoatrial node, inhibiting the inward mixed Na⁺/K⁺ current that drives spontaneous depolarisation. This action slows the pacemaker activity, producing a dose‑dependent reduction in heart rate without affecting myocardial contractility, ventricular repolarisation, or blood pressure.

Side Effects

Ivabradine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

Visual disturbances (phosphenes or luminous phenomena)
Bradycardia (heart rate below 50 bpm)
Headache
Dizziness or light‑headedness
Fatigue or weakness
Nausea

Serious or Rare Side Effects

Symptomatic bradycardia requiring medical intervention
Atrial fibrillation or other supraventricular arrhythmias
Severe hypotension
Persistent visual impairment
Hepatic dysfunction or elevated liver enzymes

Precautions & Warnings

Before initiating therapy, clinicians should evaluate cardiac status and concomitant medications.

Cardiac monitoring: assess resting heart rate and ECG prior to start.
Contraindicated in severe hypotension: avoid if systolic BP <90 mmHg.
Caution in sick‑sinus syndrome: risk of excessive bradycardia.
Avoid strong CYP3A4 inhibitors: may increase plasma levels.
Use with caution in hepatic impairment: dose adjustment may be required.
Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Ivabradine interacts with several drug classes that influence heart rate or its metabolism.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole)
Other bradycardic agents (beta‑blockers, diltiazem, verapamil)
Concomitant use with other If channel blockers

Moderate Interactions (Monitor Closely)

CYP3A4 inducers (rifampicin, carbamazepine, phenytoin)
Digoxin (pharmacodynamic interaction affecting cardiac rhythm)
Diuretics that may cause electrolyte shifts influencing heart rate

Frequently Asked Questions

Ivabradine Pharmathen is indicated for chronic stable angina and for heart failure with reduced ejection fraction in patients who need additional heart‑rate reduction despite optimal standard therapy. It helps relieve angina symptoms and can improve functional status in heart‑failure patients.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, which is responsible for spontaneous pacemaker activity. By inhibiting this inward Na⁺/K⁺ current, the drug slows the rate of depolarisation, resulting in a controlled reduction of heart rate without affecting contractility or blood pressure.

The dose of Ivabradine Pharmathen is determined by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and concomitant therapies. The prescriber will select the appropriate strength and dosing schedule according to approved labeling and individual patient needs.

The safety of Ivabradine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and can influence contractility and bronchial tone, making ivabradine a useful alternative when beta‑blockers are contraindicated or not tolerated.

Ivabradine Pharmathen tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Ivabradine Pharmathen is taken orally, usually with or without food, as directed by the prescribing physician. The tablets are swallowed whole with a glass of water and should be taken at the same times each day to maintain consistent blood levels.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and persistent visual disturbances. Patients should be monitored for these events, especially during dose initiation and when combined with other heart‑rate‑lowering agents.

Ivabradine Pharmathen is contraindicated in patients with severe hypotension, sick‑sinus syndrome, acute myocardial infarction, unstable angina, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of its excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.